StockData
Jade Biosciences, Inc. logo

Jade Biosciences, Inc. (JBIO) stock

JBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 7/30
$15.40+0.06 (+0.42%)

Close on Nov 17, 2026Market cap $979.40MP/E –Yield –

Jade Biosciences r&d expenses

Research and development expenses are spending on new products and technology.

Jade Biosciences's R&D Expenses for the twelve months ending Sep 30, 2026 was $145.48M, up 120.1% year over year. For fiscal 2025 it was $93.12M, up 75.1% from the year before. The highest annual figure on record is $93.12M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$93.12M+75.1%
FY2024Dec 31, 2024$53.19M-17.2%
FY2023Dec 31, 2023$64.22M+66.3%
FY2022Dec 31, 2022$38.62M+157.7%
FY2021Dec 31, 2021$14.99M+88.8%
FY2020Dec 31, 2020$7.94M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$30.82M+40.0%
Q2 FY2026Jun 30, 2026$50.07M+122.0%
Q1 FY2026Mar 31, 2026$36.05M+80.1%
Q4 FY2025Dec 31, 2025$28.54M+1764.2%
Q3 FY2025Sep 30, 2025$22.01M+62.1%
Q2 FY2025Jun 30, 2025$22.55M+6.1%
Q1 FY2025Mar 31, 2025$20.02M-0.3%
Q4 FY2024Dec 31, 2024$1.53M-91.4%
Q3 FY2024Sep 30, 2024$13.58M-19.6%
Q2 FY2024Jun 30, 2024$21.25M+32.5%
Q1 FY2024Mar 31, 2024$20.08M+48.9%
Q4 FY2023Dec 31, 2023$17.81M+45.8%
Q3 FY2023Sep 30, 2023$16.88M+56.6%
Q2 FY2023Jun 30, 2023$16.03M+91.7%
Q1 FY2023Mar 31, 2023$13.49M+85.9%
Q4 FY2022Dec 31, 2022$12.22M+142.2%
Q3 FY2022Sep 30, 2022$10.78M+215.5%
Q2 FY2022Jun 30, 2022$8.36M+93.3%
Q1 FY2022Mar 31, 2022$7.26M+230.4%
Q4 FY2021Dec 31, 2021$5.05M+53.0%
Q3 FY2021Sep 30, 2021$3.42M+73.9%
Q2 FY2021Jun 30, 2021$4.33M+194.2%
Q1 FY2021Mar 31, 2021$2.20M–
Q4 FY2020Dec 31, 2020$3.30M–
Q3 FY2020Sep 30, 2020$1.97M–
Q2 FY2020Jun 30, 2020$1.47M–

More Jade Biosciences figures

See a number that looks wrong?